Genprex receives ODD for Immunogene Therapy for treatment of SCLC

Genprex announces its placement in an editorial published by NetworkNewsWire. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex was granted FDA orphan drug designation, ODD, for its REQORSA immunogene therapy in development for the treatment of small cell lung cancer, SCLC.